Immunotec Mourns the Death of Dr. Gustavo Bounous

(TSX VENTURE:IMM)

Editors Note: A photo for this release will be available on the Canadian Press
picture wire via Marketwire.


It is with profound sadness that Immunotec Inc. Executive Chairman and CEO
Robert M. Henry announces the passing of Dr. Gustavo Bounous at the age of
eighty-three.


Born in Luserna, Italy in 1928 and educated at the University of Turin and the
University of Genoa, Dr. Gustavo Bounous' distinguished career in medical
research began as a Research Fellow in surgery at the Indiana Medical Center,
Indianapolis led to his appointment as Professor of Surgery, first at the
University of Sherbrooke (1973-1985) and then at McGill University (1985-1993).
Dr. Bounous was awarded the 1965 medal of the Royal College of Physicians and
Surgeons of Canada. In 1968, he was named Career Investigator of the Medical
Research Council, an award that was reconfirmed until 1993, the year of his
retirement from McGill University.


In 1978, Dr. Bounous initiated a novel research program in conjunction with
colleagues from the McGill University Faculty of Medicine to search for a
dietary protein source that would boost the immune system. Their research led to
the isolation and preparation of an undenatured milk concentrate that helps to
sustain normal glutathione levels and a strong immune system. Subsequent
identification of the active ingredients present in this protein mixture led to
the development of a high-quality bioactive material given the name Immunocal(R)
which was trademarked in 1993. Dr. Bounous later commented: "Discoveries are not
made by scientific committee; they're made by individuals who have been lucky
and persistent."


"Dr. Bounous leaves behind an incredible legacy," notes Robert Henry. "His
research led to the development of a product that has impacted many thousands of
lives. During this time of great loss, it is comforting to realize that his
genius did not merely exist in a research laboratory, but lives on in the
improved health of the many, many people who have benefited from Immunocal."


Immunotec Co-founder, Dieter Beer, funded Dr. Bounous' work after his retirement
and invested in the early patents for Immunocal. He remembers Dr. Bounous as a
very likeable man of vision, who was the embodiment of enthusiasm and humor.
"One of the major events of my life was the opportunity to meet and work with
him," he said. "He has had a profound impact on me for which I am very
grateful."


Immunotec Vice-President, Research & Development, John Molson worked at the
right-hand of Dr. Bounous for over ten years. "Most of us spend our lives
witnessing genius from afar, whether it is a young prodigy in a concert hall or
a professional athlete executing a move in a sporting match that defies the laws
of physics. To have had the opportunity to work with one whose brilliance
extended far beyond that of his scientific endeavors was to say the least, a
life-changing experience. I feel deeply privileged to have met and worked with a
true genius whose work will make a difference in the lives of millions for
generations to come."


Son of the late Ada and Carlo Bounous, Dr. Bounous is survived by his beloved
sister Luciana Bounous living in Italy. He will be missed by many friends and
colleagues that enjoyed his great wit and charm, and equally by the thousands of
individuals that have been helped by his extraordinary contributions to medical
research.


Contributions in memory of Dr. Bounous may be made in his name to the charity of
your choice.


About Immunotec Inc.

Immunotec is a network marketing company, offering a world-class business
opportunity, supported by unique, scientifically-proven health products. Its
cornerstone product, Immunocal(R), is clinically proven to optimize the immune
system. Headquartered near Montreal, Canada, the Company operates seamlessly in
Canada, the United States, Mexico, the United Kingdom, Ireland and the
Caribbean.


The Company files its press releases and such other required documents on the
SEDAR database at www.sedar.com and on the Company's website at
www.immunotec.com. The common shares of the Company are listed on the TSX
Venture Exchange under the ticker symbol IMM.


CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are
subject to numerous risks and uncertainties, known and unknown. For information
identifying known risks and uncertainties and other important factors that could
cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and Uncertainties
in Immunotec's most recent Management's Discussion and Analysis, which can be
found at www.sedar.com. Consequently, actual results may differ materially from
the anticipated results expressed in these forward-looking statements.


To view the photo associated with this press release, please visit the following
link: http://www.marketwire.com/library/20111229-Bounous_Immunotec_800.jpg